The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

acetylon.com

Stage

Acquired | Acquired

Total Raised

$156.1M

About Acetylon Pharmaceuticals

Acetylon Pharmaceuticals is a provider in the development of small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company's epigenetic drug discovery platform has yielded a portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon's lead drug candidate, ACY-1215, is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma.

Acetylon Pharmaceuticals Headquarter Location

70 Fargo Street Suite 205

Boston, Massachusetts, 02210,

United States

617-245-1300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Acetylon Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Acetylon Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Acetylon Pharmaceuticals Patents

Acetylon Pharmaceuticals has filed 48 patents.

The 3 most popular patent topics include:

  • Histone deacetylase inhibitors
  • Transcription factors
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/7/2017

5/10/2022

Histone deacetylase inhibitors, Transcription factors, Monoclonal antibodies, Experimental cancer drugs, Proteins

Grant

Application Date

8/7/2017

Grant Date

5/10/2022

Title

Related Topics

Histone deacetylase inhibitors, Transcription factors, Monoclonal antibodies, Experimental cancer drugs, Proteins

Status

Grant

Latest Acetylon Pharmaceuticals News

Adavosertib monotherapy active in recurrent uterine serous carcinoma

May 3, 2021

Disclosures: AstraZeneca supported the study. Liu reports consultant/advisory roles with AstraZeneca, Clovis Oncology, GlaxoSmithKline, Genentech/Roche, Mersana, Regeneron and Tesaro; research funding from Acetylon Pharmaceuticals, Agenus, Aravive, Arch Oncology, AstraZeneca, Atara Biotherapeutics, Boston Biomedical, Bristol Myers Squibb, Clovis Oncology, CytomX Therapeutics, Genentech/Roche, Regeneron, Surface Oncology, Tesaro, 2X Oncology and Vigeo Therapeutics; and travel, accommodations and expenses from AstraZeneca and Merck. Please see the study for all other authors’ relevant financial disclosures. Madariaga reports honoraria from AstraZeneca. Oza reports research funding from AstraZeneca, Clovis Oncology and GlaxoSmithKline. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Adavosertib demonstrated clinical activity among women with recurrent uterine serous carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology. “Uterine serous carcinoma is a distinct histologic subtype of endometrial cancer that accounts for up to 40% of endometrial cancer deaths and for which effective therapies are limited,” Joyce F. Liu, MD, MPH, researcher in the department of medical oncology at Dana-Farber Cancer Institute, and colleagues wrote. “Molecular characterization of uterine serous carcinoma suggests the presence of concomitant cell-cycle dysregulation and high replication stress that might predict for increased sensitivity to Wee1 inhibition.” Data were derived from Liu JF, et al. J Clin Oncol. 2021;doi: 10.1200/JCO.20.03167. The single-arm, two-stage study included 34 women (median age, 70.2 years; 85.3% white) with recurrent uterine serous carcinoma and a median three (range, 1-8) prior lines of therapy who received the oral Wee1 inhibitor adavosertib (AZD1775, AstraZeneca) at an initial dose of 300 mg once daily on the first 5 days and days 8 to 12 of a 21-day cycle. Treatment continued until disease progression or unacceptable toxicity. Objective response rate and 6-month PFS rate served as co-primary endpoints. Median follow-up was 5.9 months (95% CI, 4-7.2). Results showed 10 responses to treatment, including one confirmed complete response, eight confirmed partial responses and one unconfirmed partial response. This translated to an ORR of 29.4% (95% CI, 15.1-47.5). Responses appeared durable, according to researchers, who reported a median duration of response of 9 months. Sixteen women remained progression-free at 6 months, which corresponded to a PFS rate of 47.1% (95% CI, 29.8-64.9). Median PFS was 6.1 months (95% CI, 4.2-9.9). More than half (61.8%) of women in the study experienced grade 3 or higher treatment-related adverse events. Hematologic adverse events associated with adavosertib appeared common and included anemia (67.6%; grade 3, 23.5%), platelet count decrease (61.8%; grade 3, 17.6%) and neutrophil count decrease (44.1%; grade 3, 32.4%). Other common nonhematologic adverse events included diarrhea (76.5%), fatigue (64.7%) and nausea (61.8%). Next-generation sequencing revealed that tumors of all 32 women with available archival specimens had a TP53 mutation, with 31% having evidence of amplification or gain in CCNE1. Moreover, 19% of tumors had alterations in KRAS and 41% in PIK3CA. “This is the first report of clinical activity of a cell cycle or replication stress targeting agent in uterine serous carcinoma,” Liu and colleagues wrote. “These results warrant further exploration and validation; if confirmed, adavosertib monotherapy could represent a novel therapeutic option for women with uterine serous carcinoma.” In an editorial accompanying the study, Ainhoa Madariaga, MD, and Amit M. Oza, MD, both researchers at Princess Margaret Cancer Center in Toronto, noted the challenges of fully mastering adavosertib, which builds on tumor-based drivers such as TP53 and inherent replication stress to cause mitotic catastrophe. They noted that the drug previously showed efficacy among women with ovarian cancer in single-arm and randomized trials. “The current more subtle and elegant approach at improving therapy in uterine serous carcinoma by redefining chronic single-agent dosing strategies suggests a major therapeutic breakthrough and, if confirmed, will hopefully continue to navigate through a narrow therapeutic window with great effect,” Madariaga and Oza wrote. “There is much more to do, and racial differences and disparities that indicate poorer survival and higher rates of nonendometrioid endometrial cancer subtypes within Black women need to be addressed. Efforts should continue to include underrepresented populations in clinical trials striving for clinically meaningful, cost-effective and well-tolerated therapies.” References:

You May Also Like

Y
Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

P
Proteologics

PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.

B
Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

V
Virdante Pharmaceuticals

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. The company's products incorporate a proprietary sialic switch technology to improve the anti-inflammatory properties of antibodies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.